Sculptor Capital’s ImmunityBio IBRX Stock Holding History

Sculptor Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$767K	Buy	+100,000	New	+$685K	0.01%	257
2025 Q3	–	Sell	-610,000	Closed	-$1.61M	–	387
2025 Q2	$1.61M	Buy	610,000 +557,000	+1,051%	+$1.5M	0.02%	229
2025 Q1	$160K	Buy	+53,000	New	+$161K	﹤0.01%	263
2024 Q4	–	Sell	-200,000	Closed	-$744K	–	341
2024 Q3	$744K	Sell	200,000 -155,000	-44%	-$717K	0.01%	210
2024 Q2	$2.24M	Buy	355,000 +105,000	+42%	+$692K	0.04%	139
2024 Q1	$1.34M	Buy	+250,000	New	+$1.13M	0.03%	152

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sculptor Capital's IBRX Position: Q1 2026 in Review

Sculptor Capital reduced its ImmunityBio (IBRX) stake by 86% in Q1 2026, selling an estimated $3.63M and leaving 89,200 shares worth $684K. The position accounts for 0.01% of the portfolio, ranked #259.

Sculptor Capital first reported a position in IBRX in Q4 2020 and has held it in 19 quarters since. The position peaked at $3.75M in Q1 2021. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Sculptor Capital held 89,200 shares of ImmunityBio worth $684K as of Q1 2026.
Sculptor Capital sold 529,800 ImmunityBio shares in Q1 2026, an estimated $3.63M.
ImmunityBio made up 0.01% of Sculptor Capital's portfolio in Q1 2026, its #259 holding.
Sculptor Capital first reported a position in ImmunityBio in Q4 2020 and has held it in 19 quarters since.
Sculptor Capital's ImmunityBio position peaked at $3.75M in Q1 2021.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Sculptor Capital's 13F filing for Q1 2026, filed 15 May 2026.